-150x150.jpg)
The city of Jacobina, Brazil in the Bahia region was selected as the ideal area for a study designed to control disease-bearing mosquitoes. A recent report in the Science…
According to a story from Angioedema News, a recent study has found that the drug icatibant (marketed as Firazyr) can safely treat older patients with hereditary angioedema, a rare condition…
According to a story from Angioedema News, the results of a recent study have led authors to conclude that genetic testing can be useful for the diagnosis of hereditary angioedema…
According to a story from rheumatology.medicinematters.com, a recent Italian real-world study has provided some evidence that the drug apremilast, which is considered a phosphodiesterase-4 inhibitor, could be a useful treatment…
According to a press release from French biotechnology company Abivax, the Company has successfully begun recruitment for its phase 2b clinical study of ABX464, its experimental once-a-day ulcerative colitis medication.…
According to a story from Infectious Disease Advisor, a study has found that infection with the hepatitis C virus and cryoglobulinemia (high levels of cold sensitive antibodies) can lead to…
According to a story from Angioedema News, a recent clinical trial has demonstrated that the drug conestat alfa (marketed as Ruconest) was able to successfully treat 96 percent of acute…
According to a story from Angioedema News, a team of researchers has used data from a recent study to provide up to date recommendations for diagnosing hereditary angioedema in the…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
